Literature DB >> 20370678

Adipocytokines in nonalcoholic fatty liver disease: key players regulating steatosis, inflammation and fibrosis.

Herbert Tilg.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) represents the hepatic manifestation of the metabolic syndrome and covers a large spectrum of liver diseases ranging from benign steatosis to steatohepatitis, cirrhosis and hepatocellular carcinoma. The pathogenesis of NAFLD is currently believed to involve various hits including lipotoxicity, gut-derived signals, inflammatory attacks directed by proinflammatory cytokines, oxidative stress and others. All these factors finally lead to the development of necroinflammation and fibrosis in a substantial proportion of patients. There is increasing evidence that mediators released from the adipose tissue in obese subjects, such as adipocytokines and classical cytokines, are key players in NAFLD. The prototypic adipocytokines adiponectin and leptin are able to regulate many features of NAFLD such as accumulation of liver fat, insulin resistance, inflammatory processes and development of fibrosis. Therefore, this heterogenous and rapidly growing family of mediators elegantly explains many aspects of NAFLD as demonstrated by numerous experimental and clinical studies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20370678     DOI: 10.2174/138161210791208929

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  20 in total

1.  Non-alcoholic fatty liver disease in patients with migraine.

Authors:  Asuman Celikbilek; Mehmet Celikbilek; Aylin Okur; Serkan Dogan; Elif Borekci; Mustafa Kozan; Sebnem Gursoy
Journal:  Neurol Sci       Date:  2014-04-23       Impact factor: 3.307

Review 2.  Signal transductions and nonalcoholic fatty liver: a mini-review.

Authors:  Lu Zeng; Wai J Tang; Jin J Yin; Bei J Zhou
Journal:  Int J Clin Exp Med       Date:  2014-07-15

3.  A defect in the activities of Δ and Δ desaturases and pro-resolution bioactive lipids in the pathobiology of non-alcoholic fatty liver disease.

Authors:  Undurti N Das
Journal:  World J Diabetes       Date:  2011-11-15

4.  Visfatin levels in nonalcoholic fatty liver disease.

Authors:  Erdem Akbal; Erdem Koçak; Adnan Taş; Enver Yüksel; Seyfettin Köklü
Journal:  J Clin Lab Anal       Date:  2012-02       Impact factor: 2.352

5.  Diet high in fructose promotes liver steatosis and hepatocyte apoptosis in C57BL/6J female mice: Role of disturbed lipid homeostasis and increased oxidative stress.

Authors:  Youngshim Choi; Mohamed A Abdelmegeed; Byoung-Joon Song
Journal:  Food Chem Toxicol       Date:  2017-03-01       Impact factor: 6.023

6.  Nonalcoholic fatty liver disease and the heart in children and adolescents.

Authors:  Lucia Pacifico; Claudio Chiesa; Caterina Anania; Antonio De Merulis; John Frederick Osborn; Sara Romaggioli; Eugenio Gaudio
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

7.  Population-based risk factors for elevated alanine aminotransferase in a South Texas Mexican-American population.

Authors:  Hui-Qi Qu; Quan Li; Megan L Grove; Yang Lu; Jen-Jung Pan; Anne R Rentfro; Perry E Bickel; Michael B Fallon; Craig L Hanis; Eric Boerwinkle; Joseph B McCormick; Susan P Fisher-Hoch
Journal:  Arch Med Res       Date:  2012-09-05       Impact factor: 2.235

Review 8.  Molecular pathways in non-alcoholic fatty liver disease.

Authors:  Alba Berlanga; Esther Guiu-Jurado; José Antonio Porras; Teresa Auguet
Journal:  Clin Exp Gastroenterol       Date:  2014-07-05

9.  Allergic contact dermatitis is associated with significant oxidative stress.

Authors:  S Kaur; K Zilmer; V Leping; M Zilmer
Journal:  Dermatol Res Pract       Date:  2014-08-11

Review 10.  Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation.

Authors:  William Peverill; Lawrie W Powell; Richard Skoien
Journal:  Int J Mol Sci       Date:  2014-05-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.